

## Supplemental Data


### **Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in *PTPN11*-associated Noonan syndrome with Multiple Lentigines**

Jae-Sung Yi<sup>1</sup>, Sravan Perla<sup>1</sup>, Liz Enyenihi<sup>2</sup>, and Anton M. Bennett<sup>1,3,\*</sup>


<sup>1</sup>Department of Pharmacology and <sup>3</sup>Program in Integrative Cell Signaling and Neurobiology of Metabolism,  
Yale University, New Haven, CT, 06520, <sup>2</sup>Emory University, Atlanta, GA 30322

\*To whom correspondence should be addressed.


Anton M. Bennett, Ph.D.  
Yale University School of Medicine  
Department of Pharmacology,  
SHM B226D  
333 Cedar Street  
New Haven, CT 06520-8066  
E-mail: [anton.bennett@yale.edu](mailto:anton.bennett@yale.edu)




**Supplemental Figure 1. Generation of *Mpz11<sup>Y242F</sup>* allele.** (A) Schematic of the Cas9/sgRNA/oligo-targeting site at *Mpz11* exon 6. The sgRNA coding sequence is underlined, capitalized and labeled in red. The protospacer adjacent motif (PAM) sequence is labeled in green. The mutations of *AgeI* and Y242F are labeled in orange. The oligo donor has a 60 bp homology on both sides of the mutated sequence. The location of PCR primers used for genotyping are shown as green arrows. (B) Genotyping PCR and subsequent *AgeI* digestion produced bands with the correct size in *Mpz11<sup>Y242F</sup>* heterozygotes (*Mpz11<sup>+/Y242F</sup>*) and homozygotes (*Mpz11<sup>Y242F/Y242F</sup>*), but not in WT (*Mpz11<sup>+/+</sup>*). (C) PCR products generated from genotyping in (B) were sequenced. Sequence across the targeting region confirmed correct mutations (\*) in exon 6 of *Mpz11* gene.




**Supplemental Figure 2. Post-developmental characterization of PZR<sup>Y242F</sup> mice.** (A) Post-developmental body weight of WT (*Mpz11*<sup>+/+</sup>) and PZR<sup>Y242F</sup> (*Mpz11*<sup>Y242F/Y242F</sup>) mice. (B and C) Lung, liver, spleen, kidney weight (B), body weight (B.W.), heart weight (H.W.), tibia length (T.L.), the ratio of heart weight to body weight (H.W./B.W.) and heart weight to tibia length (H.W./T.L.) were measured from 20-weeks-old PZR<sup>Y242F</sup> mice (C) (n = 9 for WT and n = 10 for PZR<sup>Y242F</sup>). All data represent mean ± SEM. Statistical significance was analyzed with Two-way ANOVA (A) or two-tailed Student's t-test (B and C).




**Supplemental Figure 3. Expression of cardiomyopathy-related genes in PZR<sup>Y242F</sup> mice.** Relative mRNA expression levels of *Myh6*, *Myh7* and ratio of *Myh7/Myh6* (A), *Nppa*, *Nppb* (B) and *Col1a* (C) in the heart of 20-week-old WT (*Mpz11*<sup>+/+</sup>) and PZR<sup>Y242F</sup> (*Mpz11*<sup>Y242F/Y242F</sup>) mice were measured by quantitative RT-PCR ( $n = 7$  for each group). All data represent mean  $\pm$  SEM. Statistical significance was analyzed by two-tailed Student's t-test.




**Supplemental Figure 4. Schematic of NSML/PZR<sup>Y242F</sup> mice generation.** NSML mice (*Ptpn11*<sup>Y279C/+</sup>) were crossed with PZR<sup>Y242F</sup> mice (*Mpz1*<sup>Y242F/Y242F</sup>). Heterozygotes (*Ptpn11*<sup>Y279C/+</sup>;*Mpz1*<sup>+/Y242F</sup>) in the first generation were back-crossed with PZR<sup>Y242F</sup> mice. The resultant four genotypes are shown WT (*Ptpn11*<sup>+/+</sup>;*Mpz1*<sup>+/Y242F</sup>), NSML (*Ptpn11*<sup>Y279C/+</sup>;*Mpz1*<sup>+/Y242F</sup>), PZR<sup>Y242F</sup> (*Ptpn11*<sup>+/+</sup>;*Mpz1*<sup>Y242F/Y242F</sup>) and NSML/PZR<sup>Y242F</sup> (*Ptpn11*<sup>Y279C/+</sup>;*Mpz1*<sup>Y242F/Y242F</sup>).



**Supplemental Figure 5. Body weight and tibia length of NSML/PZR<sup>Y242F</sup> mice.** (A) Body weight of WT (*Ptpn11*<sup>+/+</sup>; *Mpz11*<sup>+/Y242F</sup>), NSML (*Ptpn11*<sup>Y279C/+</sup>; *Mpz11*<sup>+/Y242F</sup>), PZR<sup>Y242F</sup> (*Ptpn11*<sup>+/+</sup>; *Mpz11*<sup>Y242F/Y242F</sup>) and NSML/PZR<sup>Y242F</sup> (*Ptpn11*<sup>Y279C/+</sup>; *Mpz11*<sup>Y242F/Y242F</sup>) mice were measured weekly from the age of 3 weeks to 16 weeks. (B) Body weight (B.W.) and tibia length (T.L.) were measured from 16-week-old mice (n = 10 for WT and NSML, n = 9 for PZR<sup>Y242F</sup> and NSML/PZR<sup>Y242F</sup>). All data represent mean ± SEM. Statistical significance was analyzed by Two-way ANOVA (A) or One-way ANOVA with multiple comparisons, Two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli (B).




**Supplemental Figure 6. PCA plot of RNA-seq data.** Three dimensional principal component analysis (PCA) was carried out on the different genotypes (WT (*Ptpn11*<sup>+/+</sup>; *Mpz11*<sup>+/Y242F</sup>), NSML (*Ptpn11*<sup>Y279C/+</sup>; *Mpz11*<sup>+/Y242F</sup>), PZR<sup>Y242F</sup> (*Ptpn11*<sup>+/+</sup>; *Mpz11*<sup>Y242F/Y242F</sup>) and NSML/PZR<sup>Y242F</sup> (*Ptpn11*<sup>Y279C/+</sup>; *Mpz11*<sup>Y242F/Y242F</sup>)) based on 185 genes ( $p < 0.01$ ). Each spot represents an individual mouse and colored according to the corresponding genotypes. The percentage of the total variance (64%) described by each of the three principal components is given in the parentheses near each axis.




**Supplemental Figure 7. PZR tyrosyl phosphorylation is required for IL6 expression and secretion upon fibronectin engagement.** Mouse embryonic fibroblasts (MEFs) from WT (*Mpz11*<sup>+/+</sup>) and PZR<sup>Y242F</sup> (*Mpz11*<sup>Y242F/Y242F</sup>) mice were serum-starved, trypsinized, suspended and then plated onto fibronectin-coated petri dish for 1 hr. (A) Total RNA was isolated and the relative expression of *Il6* was measured by quantitative RT-PCR. (A) Medium was collected and secreted IL6 levels measured by ELISA ( $n = 3$  for each group). All data represent mean  $\pm$  SEM. Statistical significance was analyzed with Two-way ANOVA with multiple comparisons, Two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli.





**Supplemental Figure 8. PZR tyrosyl phosphorylation is required for IL6 expression. (A-C)** Human PZR WT cDNA was overexpressed into PZR<sup>Y242F</sup> (*Mpz11*<sup>Y242F/Y242F</sup>) MEFs. Whole cell lysates were immunoblotted with anti-pPZR (Y242), pPZR (Y264) and PZR antibodies (A). Total RNA was isolated and the relative expression of *Il6* was measured by quantitative RT-PCR (B) (n = 3). After serum starvation, cells were stimulated with 5  $\mu$ g/ml of Concanavalin A (ConA) for 1, 2 and 4 hr. Total RNA was isolated and the relative expression of *Il6* was measured by quantitative RT-PCR (C) (n = 3). All data represent mean  $\pm$  SEM. Statistical significance was analyzed with One-way ANOVA with multiple comparisons, Two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli (B) or Two-way ANOVA (C).



**Supplemental Figure 9. NFκB signaling is required for Concanavalin A-induced IL6 expression.** (A-D) WT (*Mpz11*<sup>+/+</sup>) MEFs were treated with dasatinib (A), IKK-16 (B), JSH23 (C) and GYY4137 (D) for 16 hr with the indicated concentrations, and then stimulated with 5 μg/ml of Concanavalin A (ConA) for 1 hr. Total RNA was isolated and the relative expression of *Il6* was measured by quantitative RT-PCR (n = 3). Medium was collected and secreted IL6 levels measured by ELISA (n = 3). (E) Human PZR WT cDNA was overexpressed into PZR<sup>Y242F</sup> MEFs. Cells were treated with 50 nM dasatinib (Das), 0.5 μM IKK-16 (IKK), 50 μM JSH23 (JSH) and 1 mM GYY4137 (GYY) for 16 hr, and then were stimulated with 5 μg/ml of Concanavalin A for 1 hr. Total RNA was isolated and the relative expression of *Il6* was measured by quantitative RT-PCR (n = 3). All data represent mean ± SEM. Statistical significance was analyzed with One-way ANOVA with multiple comparisons.

		WT	<i>Mpz11</i> <sup>+/<i>Y242F</i></sup>	<i>Mpz11</i> <sup><i>Y242F</i>/<i>Y242F</i></sup>	$\chi^2$	<i>p</i>	<i>n</i>
P10	All	88	183	93	0.1484	0.9285	364
	Male	46	96	42	0.5217	0.7704	184
	Female	42	87	51	1.1000	0.5769	180

**Supplemental Table 1. Mendelian inheritance in the offspring of PZR<sup>Y242F</sup> mice.**

	WT (n=6)	PZR <sup>Y242F</sup> (n=7)
IVS,d (mm)	0.66±0.02	0.69±0.03
IVS,s (mm)	1.10±0.03	1.12±0.06
LVID,d (mm)	3.94±0.15	3.65±0.11
LVID,s (mm)	2.70±0.13	2.39±0.09
LVPW,d (mm)	0.75±0.03	0.85±0.04
LVPW,s (mm)	1.10±0.06	1.23±0.05
LV vol,d (mm <sup>3</sup> )	68.21±6.08	56.48±4.07
LV vol,s (mm <sup>3</sup> )	27.47±3.20	20.09±1.90
%EF	60.10±1.70	64.57±1.51
%FS	31.59±1.12	34.60±1.11

**Supplemental Table 2. Echocardiography parameters of 16-week-old WT (*Mpz11*<sup>+/+</sup>) and PZR<sup>Y242F</sup> (*Mpz11*<sup>Y242F/Y242F+</sup>) mice.** Data represents the mean ± SEM for WT (n=6) and PZR<sup>Y242F</sup> (n=7). IVS, Intraventricular septum wall thickness; LVID, left ventricular internal dimension; LVPW, left ventricular posterior wall thickness; LV vol, left ventricle volume; EF, ejection fraction; FS, fractional shortening; d, diastole; s, systole.

	WT (n=7)	NSML (n=7)	PZR <sup>Y242F</sup> (n=7)	NSML/PZR <sup>Y242F</sup> (n=7)
IVS,d (mm)	0.81±0.03	0.91±0.03*	0.77±0.03 <sup>†††</sup>	0.81±0.02 <sup>†</sup>
IVS,s (mm)	1.38±0.05	1.33±0.05	1.17±0.03 <sup>**†</sup>	1.18±0.06 <sup>**†</sup>
LVID,d (mm)	4.01±0.08	4.16±0.09	4.20±0.06	4.24±0.12
LVID,s (mm)	2.58±0.09	2.73±0.12	2.74±0.11	2.78±0.09
LVPW,d (mm)	0.81±0.01	0.91±0.05*	0.81±0.01 <sup>†</sup>	0.82±0.01 <sup>†</sup>
LVPW,s (mm)	1.12±0.05	1.22±0.05	1.09±0.04	1.17±0.03
LV vol,d (mm <sup>3</sup> )	71.35±3.48	79.02±3.69	78.80±3.26	83.09±5.18
LV vol,s (mm <sup>3</sup> )	24.5±2.17	28.35±3.01	28.56±2.75	29.38±2.22
%EF	65.94±1.75	64.35±3.17	63.97±2.84	64.62±1.66
%FS	35.97±1.33	35.12±2.33	34.79±2.17	35.14±1.23

**Supplemental Table 3. Echocardiography parameters of 20-week-old WT (*Ptpn11*<sup>+/+</sup>;*Mpz11*<sup>+/Y242F</sup>), NSML (*Ptpn11*<sup>Y279C/+</sup>;*Mpz11*<sup>+/Y242F</sup>), PZR<sup>Y242F</sup> (*Ptpn11*<sup>+/+</sup>;*Mpz11*<sup>Y242F/Y242F</sup>) and NSML/PZR<sup>Y242F</sup> (*Ptpn11*<sup>Y279C/+</sup>;*Mpz11*<sup>Y242F/Y242F</sup>) mice.** Data represents the mean ± SEM. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$  denotes significance compared with WT mice. †,  $p < 0.05$ ; ††,  $p < 0.01$  denotes significance compared with NSML mice. All  $p$  values were derived using One-way ANOVA with multiple comparisons. IVS, Intraventricular septum wall thickness; LVID, left ventricular internal dimension; LVPW, left ventricular posterior wall thickness; LV vol, left ventricle volume; EF, ejection fraction; FS, fractional shortening; d, diastole; s, systole.

Name	Sequences
Guide Mpzl1-2 primer	5'-TGTAATACGACTCACTATAGGTCTAACTGTGCGTA AATGACGTTTTAGAGCTAGAAA-3'
sgRNA reverse primer	5'-AAAAGCACCGACTCGGTGCC-3'
Cas9FWpX330 primer	5'-TGTAATACGACTCACTATAGGGAGAATGGACTATA AGGACCACGAC-3'
Cas9revpX330 primer	5'-GCGAGCTCTAGGAATTCTTAC-3'
Template ssODN	5'-TCCTGTGGCTCAGGGACCATCAGTTCTTCCAAACCT CTAATTGGTTTCTTCTCCAGGGACCGGTCATTTTCG CACAGTTAGACCACTCTGGCGGACACCACAGCGGCAA GATTAATAAGTCAGAGTCGGTTGTGTTTGC GGACATCC GGAAAGACTAAGAGAACACCCAAACATTTCCAAACTG GACGCTTGTGCAGA-3'

**Supplemental Table 4. Oligo nucleotide sequences for *Mpzl1*<sup>Y242F</sup> mutant mice generation.**

Primer Name	Sequences
18S rRNA	5'-ACCGCAGCTAGGAATAATGGA-3' 5'-ACCAAAAGCCTTGACTCCG-3'
<i>Myh6</i>	5'-GTCCCGGACACTGGACCAGGCC-3' 5'-CTCCTTTTCTTCCAGTTGCCTAGCCAA-3'
<i>Myh7</i>	5'-GAGCAAGGCCGAGGAGACGCAGCGT-3' 5'-GAGCCTCCTTCTCGTCCAGCTGCCGG-3'
<i>Nppa</i>	5'-CCTGGAGGAGAAGATGCCGGTAGAA-3' 5'-CCCCAGTCCAGGGAGGCACCTCGG-3'
<i>Nppb</i>	5'-CACTTCAAAGGTGGTCCCAGAGCTGC-3' 5'-GACCGGATCGGATCCGTCAGTCG-3'
<i>Colla</i>	5'-AGGTCTTCTGGAGCTGATG-3' 5'-ACCCACAGGGCCTTCTTTAC-3'
<i>Col3a</i>	5'-ACAGCAAATCACTTACACAGTTC-3' 5'-CTCATTGCCTTGCGTGTTT-3'
<i>Il1b</i>	5'-CCAAGCAACGACAAAATACC-3' 5'-GTTGAAGACAAACCGTTTTTCC-3'
<i>Il4</i>	5'-GGTCTCAACCCCAAGCTAGT-3' 5'-GCCGATGATCTCTCTCAAGTGAT-3'
<i>Il6</i>	5'-CCACGGCCTTCCCTACTTC -3' 5'-TGGGAGTGGTATCCTCTGTGAA -3'
<i>Il6r</i>	5'-AAGCAGCAGGCAATGTTACC-3' 5'-CATAAATAGTCCCCAGTGTCG-3'
<i>Il10</i>	5'-CTTACTGACTGGCATGAGGATCA-3' 5'-GCAGCTCTAGGAGCATGTGG-3'
<i>Il13</i>	5'-CCTGGCTCTTGCTTGCCTT-3' 5'-GGTCTTGTGTGATGTTGCTCA-3'
<i>Tnf</i>	5'-CATCTTCTCAAAATTCGAGTGACAA-3' 5'-TGGGAGTAGACAAGGTACAACCC-3'
<i>Ifng</i>	5'-TCAAGTGGCATAGATGTGGAAGAA-3' 5'-TGGCTCTGCAGGATTTTCATG-3'
<i>Crp</i>	5'-CAGACTTTTCCGCACCTTGGCTTT-3' 5'-AGTGGGTGGTGCTGAAGTACGATT-3'

**Supplemental Table 5. The list of primers for quantitative real-time PCR analysis.**